• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白塞综合征免疫生物标志物特征:一项大规模单中心真实世界研究。

Profile of immunological biomarkers in Behcet's syndrome: a large-scale single-center real-world study.

机构信息

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China.

Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.

出版信息

Clin Exp Med. 2024 Aug 28;24(1):201. doi: 10.1007/s10238-024-01462-5.

DOI:10.1007/s10238-024-01462-5
PMID:39196452
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11358242/
Abstract

Behcet's syndrome (BS) is a vasculitis characterized by immune dysregulation. Biomarkers are valuable for assessing clinically atypical pathogenesis. We aimed to investigate the distribution of different biomarkers and their effects on the clinical features of patients with BS in a large-scale, real-world study. This is a retrospective, single-center study. In total, 502 patients diagnosed with BS were enrolled in this study. We analyzed the clinical features of this cohort and divided patients' symptoms into six categories, including mucocutaneous, articular, neurological, gastrointestinal, vascular, and ocular involvements. HLA-B51 cells, autoantibodies, and subsets of immune cells from the patients were tested. Pearson's correlation, Wilcoxon rank sum test and multivariate logistic regression were used for data analysis. Various autoantibodies were detected in the serum of 40.8% of patients with BS. The positivity rate of anti-endothelial cell antibodies (AECA) was the highest among autoantibodies and was found in 23.5% (118/502) of patients with BS. The positivity rate of HLA-B51 in patients with BS was 27.1%. Tumor necrosis factor (TNF)-α, IL-2, and IL-4 producing CD4 T cells were positively correlated with the gastrointestinal BS. Increased IL-4CD4 T cell was a risk factor for gastrointestinal BS (P = 0.006, Overall rate [OR] = 2.491, 95% Confidence interval [CI]: [1.317, 5.100]). Various autoantibodies can be detected in patients with BS. HLA-B51 and AECA are the most common biomarkers. Increased IL-4 CD4 T cell was a risk factor for gastrointestinal involvement in BS.

摘要

贝赫切特综合征(BS)是一种免疫失调为特征的血管炎。生物标志物对于评估非典型的临床发病机制具有重要价值。我们旨在通过一项大规模的真实世界研究,来调查不同生物标志物的分布及其对 BS 患者临床特征的影响。这是一项回顾性、单中心研究。共纳入 502 例 BS 患者。我们分析了该队列的临床特征,并将患者的症状分为六类,包括黏膜皮肤、关节、神经、胃肠道、血管和眼部受累。检测了患者的 HLA-B51 细胞、自身抗体和免疫细胞亚群。采用 Pearson 相关分析、Wilcoxon 秩和检验和多变量逻辑回归进行数据分析。BS 患者的血清中检测到各种自身抗体。自身抗体中抗内皮细胞抗体(AECA)的阳性率最高,在 23.5%(118/502)的 BS 患者中阳性。BS 患者的 HLA-B51 阳性率为 27.1%。TNF-α、IL-2 和 IL-4 产生的 CD4 T 细胞与胃肠道 BS 呈正相关。增加的 IL-4CD4 T 细胞是胃肠道 BS 的危险因素(P=0.006,总发生率 [OR]=2.491,95%置信区间 [CI]:[1.317, 5.100])。BS 患者可检测到各种自身抗体。HLA-B51 和 AECA 是最常见的生物标志物。增加的 IL-4 CD4 T 细胞是 BS 胃肠道受累的危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f7a/11358242/15503d739e89/10238_2024_1462_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f7a/11358242/d613566e2b6f/10238_2024_1462_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f7a/11358242/598e45132cc4/10238_2024_1462_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f7a/11358242/15503d739e89/10238_2024_1462_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f7a/11358242/d613566e2b6f/10238_2024_1462_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f7a/11358242/598e45132cc4/10238_2024_1462_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f7a/11358242/15503d739e89/10238_2024_1462_Fig3_HTML.jpg

相似文献

1
Profile of immunological biomarkers in Behcet's syndrome: a large-scale single-center real-world study.白塞综合征免疫生物标志物特征:一项大规模单中心真实世界研究。
Clin Exp Med. 2024 Aug 28;24(1):201. doi: 10.1007/s10238-024-01462-5.
2
[The distribution of biomarkers for Behcet syndrome and their clinical relevance in real-world studies].[白塞病生物标志物的分布及其在真实世界研究中的临床相关性]
Zhonghua Yu Fang Yi Xue Za Zhi. 2024 Sep 6;58(9):1341-1347. doi: 10.3760/cma.j.cn112150-20231110-00332.
3
Transcriptome analysis of immune cells from Behçet's syndrome patients: the importance of IL-17-producing cells and antigen-presenting cells in the pathogenesis of Behçet's syndrome.Behçet 综合征患者免疫细胞的转录组分析:IL-17 产生细胞和抗原提呈细胞在 Behçet 综合征发病机制中的重要性。
Arthritis Res Ther. 2022 Aug 8;24(1):186. doi: 10.1186/s13075-022-02867-x.
4
When it looks like Behçet's syndrome but is something else: differential diagnosis of Behçet's syndrome: a two-centre retrospective analysis.当表现类似贝赫切特综合征但又并非该病时:贝赫切特综合征的鉴别诊断:两项中心回顾性分析。
Rheumatology (Oxford). 2023 Nov 2;62(11):3654-3661. doi: 10.1093/rheumatology/kead101.
5
The influence of HLA-B51 on clinical manifestations among Japanese patients with Behçet's disease: A nationwide survey.HLA-B51 对日本白塞病患者临床表现的影响:一项全国性调查。
Mod Rheumatol. 2020 Jul;30(4):708-714. doi: 10.1080/14397595.2019.1649103. Epub 2019 Aug 6.
6
Dose HLA-B5, 7, 8, 27, and 51 Antigens Associated to Behcet's disease? A Study in Southwestern Iran.HLA-B5、7、8、27 和 51 抗原与贝赫切特病有关吗?伊朗西南部的一项研究。
Curr Rheumatol Rev. 2020;16(2):120-124. doi: 10.2174/1573397115666190918153721.
7
The relationship between plasma homocysteine level and HLA-B51 in patients with Behcet's disease: a case-control study.白塞病患者血浆同型半胱氨酸水平与 HLA-B51 的关系:病例对照研究。
Int J Rheum Dis. 2014 May;17(4):466-70. doi: 10.1111/1756-185X.12271. Epub 2014 Jan 16.
8
HLA-B51 Impact on Clinical Symptoms in Behcet's Disease.HLA-B51 对贝赫切特病临床症状的影响。
J Coll Physicians Surg Pak. 2022 Jul;32(7):904-908. doi: 10.29271/jcpsp.2022.07.904.
9
HLA-B gene methylation and expression in Behçet's syndrome: a potential role of epigenetics in the pathogenesis.HLA-B 基因甲基化与表达在贝赫切特综合征中的作用:表观遗传学在发病机制中的潜在作用。
Clin Exp Rheumatol. 2024 Oct;42(10):2014-2020. doi: 10.55563/clinexprheumatol/1sf43v. Epub 2024 Jan 24.
10
Clinical heterogeneity of ocular Behçet's syndrome versus intestinal Behçet's syndrome: a cross-sectional study from Shanghai Behçet's syndrome database.眼型贝赫切特综合征与肠型贝赫切特综合征的临床异质性:来自上海贝赫切特综合征数据库的横断面研究。
Arthritis Res Ther. 2022 Apr 29;24(1):98. doi: 10.1186/s13075-022-02782-1.

本文引用的文献

1
Behçet's syndrome: one year in review 2023.白塞氏综合征:2023 年度综述一年。
Clin Exp Rheumatol. 2023 Oct;41(10):1945-1954. doi: 10.55563/clinexprheumatol/7kdo9x. Epub 2023 Oct 10.
2
Advances in pathogenesis and treatment of ocular involvement in Behcet's disease.贝赫切特病眼部受累的发病机制和治疗进展。
Front Immunol. 2023 Sep 29;14:1206959. doi: 10.3389/fimmu.2023.1206959. eCollection 2023.
3
Immunopathogenesis of Behçet's disease.贝赫切特病的免疫发病机制。
Clin Immunol. 2023 Aug;253:109661. doi: 10.1016/j.clim.2023.109661. Epub 2023 Jun 7.
4
The treatment principles and targets for intestinal Behcet's disease.肠道白塞病的治疗原则与目标
Therap Adv Gastroenterol. 2023 Apr 17;16:17562848231167283. doi: 10.1177/17562848231167283. eCollection 2023.
5
Factors Associated with the Development of Thrombosis in Pediatric Behçet Disease.与儿童贝赫切特病血栓形成相关的因素。
J Clin Rheumatol. 2023 Jun 1;29(4):e19-e24. doi: 10.1097/RHU.0000000000001930. Epub 2022 Dec 7.
6
Behçet's disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity.白塞病风险变体 HLA-B51/ERAP1-Hap10 改变人类 CD8 T 细胞免疫。
Ann Rheum Dis. 2022 Nov;81(11):1603-1611. doi: 10.1136/ard-2022-222277. Epub 2022 Aug 3.
7
Anti-tubulin-alpha-1c antibody as a marker of value in Behçet syndrome.抗微管蛋白-α1c 抗体在 Behçet 综合征中的价值标志物。
Clin Rheumatol. 2022 Jun;41(6):1759-1767. doi: 10.1007/s10067-021-06025-7. Epub 2022 Feb 7.
8
Immunopathogenesis of Behçet's disease and treatment modalities.贝赫切特病的免疫发病机制和治疗方法。
Semin Arthritis Rheum. 2022 Feb;52:151956. doi: 10.1016/j.semarthrit.2022.151956. Epub 2022 Jan 10.
9
Saliva and Serum Cytokine Profiles During Oral Ulceration in Behçet's Disease.贝切特病口腔溃疡期间的唾液和血清细胞因子谱。
Front Immunol. 2021 Dec 22;12:724900. doi: 10.3389/fimmu.2021.724900. eCollection 2021.
10
The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta-analysis.抗肿瘤坏死因子制剂治疗肠白塞病的疗效和安全性:系统评价和荟萃分析。
J Gastroenterol Hepatol. 2022 Apr;37(4):608-619. doi: 10.1111/jgh.15754. Epub 2022 Jan 3.